Join
Live feed
·
PRReleasevia Quantisnow
Eikon Therapeutics Inc. logo

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
EIKN· Eikon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EIKN (Eikon Therapeutics Inc.) and more on Quantisnow.